COMMUNIQUÉS West-GlobeNewswire

Virbac : Declaration of the number of shares and voting rights as of August 2017, 31.
11/09/2017
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
Virbac : Déclaration d'actions et de droits de vote au 31 Juillet 2017
11/09/2017
DECLARATION D'ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d'actions composant le capital (Article 223-16 du Règlement Général de l'Autorité des Marchés Financiers) [...]
Virbac : Declaration of the number of shares and voting rights as of July 2017, 31.
11/09/2017
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
Principal Investigator Dr. James Gulley to Provide Presentation Entitled "Therapeutic Vaccines in Prostate Cancer" at the ESMO 2017 Congress
11/09/2017
MADRID, September 11, 2017 - This morning at the European Society for Medical Oncology (ESMO) 2017 Congress, Dr. James Gulley, Chief, Genitourinary Malignancies Branch, Senior Investigator, Head, Immunotherapy Section, [...]
FIT Biotech Oy: Conversion of FIT Biotech Oy's Convertible Capital Notes into shares
11/09/2017
FIT Biotech Oy Company release September 11, 2017 at 10:00 AM EET Conversion of FIT Biotech Oy's Convertible Capital Notes into shares Related to Convertible Note and Warrant Programmes established on September 26, 2016 [...]
Solon Eiendom ASA : Primary insider notification
11/09/2017
(Oslo, Norway, 08 September 2017) Solon Eiendom ASA Chairman of the Board Simen Thorsen (through his wholly owned company Hortulan AS) has today bought 133,553 shares in Solon Eiendom ASA at a price of NOK 17.5373 per [...]
Xbrane confirms order of Spherotide to value of SEK 8.5 million and more than 10,000 doses sold
11/09/2017
Press release 2017-09-11 Xbrane has confirmed an additional order of Spherotide from Pooyesh Darou, its partner in the Middle East, to a value of SEK 8.5 million to be delivered in Q4 2017. With this delivery Xbrane [...]
Infant Bacterial Therapeutics announces that top line data demonstrate similar safety and tolerability profile in the active and placebo groups.
11/09/2017
Infant Bacterial Therapeutics and the principal investigator Dr. Josef Neu have made an initial evaluation of the top line data of the Phase II "Randomized, double blind, parallel-group, dose escalation placebo- [...]
SelectMDx Outperforms PCA3 Stratifying Men for mpMRI
11/09/2017
Test Reduces Unnecessary Invasive Procedures NEWS RELEASE IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, September 11, 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced results from a retrospective study published [...]
SelectMDx plus performant que PCA3 pour sélectionner les hommes devant passer une IRM-mp
11/09/2017
Le test limite les procédures invasives inutiles COMMUNIQUÉ DE PRESSE IRVINE, CA, et HERSTAL, BELGIQUE - 07:00 CEST, 11 septembre, 2017 - MDxHealth SA (Euronext : MDXH.BR) a annoncé les résultats d'une étude [...]
INNATE PHARMA : New preclinical data further strengthen the rationale of IPH5401 and monalizumab
11/09/2017
ICI conference 2017: NEW PRECLINICAL DATA further strengthen the rationale of IPH5401 AND MONALIZUMAB for cancer treatments and in combination with anti-PD-1/PD-L1 IPH5401, an anti-C5aR antibody, potentially reverses [...]
INNATE PHARMA: nouvelles données précliniques renforçant le rationnel d'IPH5401 et monalizumab
11/09/2017
ConfÉrence ICI 2017 : NOUVELLES donnÉes prÉcliniques RENFORcant le rationnel d'iph5401 et monalizumab dans le traitement du cancer et en combinaison avec des anti-PD-1/PD-L1 En inversant l'immunosuppression dans le [...]
First Patients Enrolled in UK's Early Access to Medicines Scheme for Santhera's Raxone® in Duchenne Muscular Dystrophy (DMD)
11/09/2017
Liestal, Switzerland, September 11, 2017 - Santhera Pharmaceuticals (SIX: SANN) announces enrollment of first DMD patients with respiratory function decline not taking glucocorticoids into UK's Early Access to Medicines [...]
Targovax ASA: Three posters presented at ESMO conference
11/09/2017
Oslo, Norway, 11 September 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces that three posters [...]
Sanofi, Regeneron: Dupilumab Hits Main Objectives in Late-Stage Asthma Trial
11/09/2017
Sanofi and Regeneron Announce Positive Dupilumab Topline Results From Phase 3 Trial in Uncontrolled Persistent Asthma - Investigational dupilumab reduced severe asthma attacks and improved lung function - Paris, France [...]
Sanofi et Regeneron annoncent les premiers résultats positifs d'une étude de phase 3 consacrée au dupilumab dans le traitement de l'asthme persistant non contrôlé
11/09/2017
Sanofi et Regeneron annoncent les premiers résultats positifs d'une étude de phase 3 consacrée au dupilumab dans le traitement de l'asthme persistant non contrôlé - L'agent expérimental dupilumab a permis de réduire les [...]
Novartis Phase III study demonstrates adjuvant Tafinlar® + Mekinist® reduced the risk of disease recurrence by 53% in patients with resected BRAF V600 mutation-positive melanoma
11/09/2017
The three-year relapse-free survival (RFS) rate for patients treated with the combination was 58%, compared to 39% with placebo[1] Consistent improvement in RFS observed across all pre-specified subgroups, including [...]
Novartis presents new data at EURETINA 2017 confirming Lucentis® efficacy and durability vs aflibercept
09/09/2017
Interim results of the head-to-head RIVAL study confirm strong efficacy and comparable durability versus aflibercept in patients with nAMD Five-year results from the Lucentis LUMINOUS study, the largest ever in retinal [...]
L'Association internationale pour l'étude du cancer du poumon annonce des sélections de rapports pour la 18e Conférence mondiale sur le cancer du poumon
08/09/2017
Des travaux de recherche révolutionnaires mettront en lumière les progrès les plus récents dans l'étude du cancer du poumon DENVER, 2017-09-08 (GLOBE NEWSWIRE) -- L'Association internationale pour l'étude du cancer du [...]

Pages